MannKind News

MannKind stock peaked in the wee hours of pre-market trading the day following a near unanimous adcom victory, but might not equal that fondly remembered price for years to come.

Today, Analysts Review released its analysts' notes regarding MannKind Corp. , Acceleron Pharma, Inc. , Steris Corp. , Retrophin, Inc. , and NxStage Medical, Inc. .

Shares of MannKind opened at 6.32 on Tuesday. MannKind has a 52 week low of $3.72 and a 52 week high of $8.70.

MannKind Updates Status of New Drug Application for AFREZZA VALENCIA, Calif., Apr 07, 2014 -- MannKind Corporation MNKD -12.25% today announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act date for AFREZZAA by three months to July 15, 2014 in order to provide time for a full review of information ... (more)

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.

MannKind's surprise recommendation of approval for its diabetic inhaler by a Food and Drug Administration panel this week provides another platform to discuss this multibillion area of pharmaceuticals.

Before the opening bell, Dow Jones futures rose 0.11% to 16,467. Futures on the S&P 500 were up 0.06% to 1,879.00.

The Food and Drug Administration controls the food on your plate and the medication used to treat your ailments.

Danbury-based MannKind's hopes for Afrezza, an inhaled diabetes drug, took a major step forward this week when an advisory panel recommended the Food and Drug Administration approve the treatment.

Toward the end of trading Wednesday, the Dow traded up 0.18 percent to 16,562.46 while the NASDAQ surged 0.05 percent to 4,270.78.

Midway through trading Wednesday, the Dow traded up 0.11 percent to 16,551.46 while the NASDAQ surged 0.09 percent to 4,271.78.

Cowen and Company's price objective would suggest a potential upside of 24.38% from the company's current price.

You will receive a download link right in your email inbox for each of the free reports that you choose.

MannKind Corporation today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration voted 13 to 1 to recommend that AFREZZA Inhalation Powder be granted marketing approval by the FDA to improve glycemic control in adults with type 1 diabetes and voted 14 to 0 to recommend that AFREZZA be ... (more)

AA shares closed up 3.13% on Monday with nearly 40 million shares traded. The stock was one of the most active stocks on the NYSE and hit a new yearly high of $12.97 during intra-day trading.

Toward the end of trading Monday, the Dow traded up 0.83 percent to 16,459.76 while the NASDAQ surged 1.12 percent to 4,202.81.

Food and Drug Administration concerns , the pharmaceutical stock is down another 16% this afternoon at $4.07, thanks to a bearish brokerage note from Piper Jaffray earlier.

YHOO shares modestly closed in the green this past Friday up almost 1%. The stock traded nearly 18.3 million shares and was one of the most active stocks on the NASDAQ.

StockTwits today are oncology concern Ariad Pharmaceuticals, Inc. and biopharmaceutical issue MannKind Corporation .

MannKind Corp.'s inhaled diabetes drug, found to be effective against Type 2 diabetes, is linked to potential breathing problems that may limit its use in patients with lung diseases, U.S. regulators said.